David I Quinn

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Molecular markers of prostate cancer outcome
    David I Quinn
    Division of Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastalke Avenue, Suite 3453, Los Angeles, CA 90033, USA
    Eur J Cancer 41:858-87. 2005
  2. doi request reprint Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma
    David I Quinn
    University of Southern California, Los Angeles, California, USA
    Clin Pharmacokinet 48:199-209. 2009
  3. pmc Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California 90033, USA
    J Nucl Med 54:1195-201. 2013
  4. doi request reprint One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer
    Kathleen Ell
    School of Social Work, University of Southern California, 669 W 34th St, Los Angeles, CA 90089 0411, USA
    Psychiatr Serv 62:162-70. 2011
  5. doi request reprint Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
    David I Quinn
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Lancet Oncol 14:893-900. 2013
  6. pmc Randomized controlled trial of collaborative care management of depression among low-income patients with cancer
    Kathleen Ell
    School of Social Work and Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 0411, USA
    J Clin Oncol 26:4488-96. 2008
  7. doi request reprint Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors
    Syma Iqbal
    Department of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA 90033, USA
    Am J Clin Oncol 34:27-31. 2011
  8. doi request reprint Blood cells and their use in active immunotherapy of prostate cancer
    Shuang Yin Zhang
    University of Southern California, Medicine, Los Angeles, CA, USA
    Hum Vaccin Immunother 8:528-33. 2012
  9. ncbi request reprint Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines
    Carmen Plasencia
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, 90089, USA
    Mol Cancer Ther 4:1105-13. 2005
  10. doi request reprint Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients
    Anirban P Mitra
    Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA Center for Personalized Medicine, University of Southern California, Los Angeles, CA
    Urol Oncol 32:52.e1-9. 2014

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Molecular markers of prostate cancer outcome
    David I Quinn
    Division of Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastalke Avenue, Suite 3453, Los Angeles, CA 90033, USA
    Eur J Cancer 41:858-87. 2005
    ..By integrating selected markers into prospective clinical trials, there is potential for us to provide specific targeted therapy tailored for an increasing number of patients...
  2. doi request reprint Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma
    David I Quinn
    University of Southern California, Los Angeles, California, USA
    Clin Pharmacokinet 48:199-209. 2009
    ..The variability of bortezomib pharmacokinetics with CYP enzyme polymorphism was also investigated...
  3. pmc Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California 90033, USA
    J Nucl Med 54:1195-201. 2013
    ..The aim of this prospective investigation was to assess the association of parameters derived from baseline (18)F-FDG PET/CT with overall survival (OS) in men with castrate-resistant metastatic prostate cancer...
  4. doi request reprint One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer
    Kathleen Ell
    School of Social Work, University of Southern California, 669 W 34th St, Los Angeles, CA 90089 0411, USA
    Psychiatr Serv 62:162-70. 2011
    ..This study assessed longer-term outcomes of low-income patients with cancer (predominantly female and Hispanic) after treatment in a collaborative model of depression care or in enhanced usual care...
  5. doi request reprint Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
    David I Quinn
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Lancet Oncol 14:893-900. 2013
    ..Atrasentan, an endothelin receptor antagonist, has shown activity in prostate cancer. We therefore assessed its effect on survival in patients with castration-resistant prostate cancer with bone metastases...
  6. pmc Randomized controlled trial of collaborative care management of depression among low-income patients with cancer
    Kathleen Ell
    School of Social Work and Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 0411, USA
    J Clin Oncol 26:4488-96. 2008
    ..To determine the effectiveness of the Alleviating Depression Among Patients With Cancer (ADAPt-C) collaborative care management for major depression or dysthymia...
  7. doi request reprint Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors
    Syma Iqbal
    Department of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA 90033, USA
    Am J Clin Oncol 34:27-31. 2011
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) and docetaxel (T) administered in 4 week cycles in patients with advanced solid tumors...
  8. doi request reprint Blood cells and their use in active immunotherapy of prostate cancer
    Shuang Yin Zhang
    University of Southern California, Medicine, Los Angeles, CA, USA
    Hum Vaccin Immunother 8:528-33. 2012
    ..We review the components of the immune system which may be harnessed in the development of immunotherapy in the setting of the recent success with sipuleucel-T...
  9. ncbi request reprint Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines
    Carmen Plasencia
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, 90089, USA
    Mol Cancer Ther 4:1105-13. 2005
    ....
  10. doi request reprint Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients
    Anirban P Mitra
    Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA Center for Personalized Medicine, University of Southern California, Los Angeles, CA
    Urol Oncol 32:52.e1-9. 2014
    ..This study was aimed at examining the sole effect of gender on postcystectomy UCB outcomes and identifying potential factors that may explain the poor prognosis in females using a balanced case-control approach...
  11. doi request reprint Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer
    Tanya B Dorff
    University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA
    Clin Genitourin Cancer 11:416-22. 2013
    ..Oxaliplatin and pemetrexed have each shown modest activity in the treatment of CRPC. Given their favorable nonoverlapping toxicity profiles, we studied them in combination...
  12. doi request reprint Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial
    Eric Cheung
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
    Clin Genitourin Cancer 7:43-50. 2009
    ..Fenretinide is a synthetic retinoid that is cytotoxic to a variety of cancers. We conducted a phase II trial of oral fenretinide in patients with biochemically recurrent prostate cancer...
  13. pmc Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
    Tanya B Dorff
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Clin Cancer Res 16:3028-34. 2010
    ..Interleukin-6 (IL-6) facilitates cancer cell survival via pleotrophic effects. We conducted a multicenter phase II study of CNTO328 (siltuximab) as second-line therapy for men with castration-resistant prostate cancer...
  14. ncbi request reprint Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer
    Guangbin Xia
    Department of Medicine, Keck School of Medicine of the University of Southern California, California, USA
    J Urol 175:1245-52. 2006
    ..Therefore, we studied the expression of VEGF and VEGFR2 in bladder cancer, and the relationship to disease characteristics...
  15. ncbi request reprint EphB4 expression and biological significance in prostate cancer
    Guangbin Xia
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, USA
    Cancer Res 65:4623-32. 2005
    ..These data show a role for EphB4 in prostate cancer and provide a rationale to study EphB4 for diagnostic, prognostic, and therapeutic applications...
  16. doi request reprint Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases
    Alev Brown
    Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA
    Urology 83:159-65. 2014
    ..To describe 3 cases of advanced refractory penile cancer treated with targeted therapy against the epidermal growth factor receptor (EGFR)...
  17. pmc Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer
    Hossein Jadvar
    Division of Nuclear Medicine, Department of Radiology, Kenneth J Norris Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Clin Nucl Med 37:637-43. 2012
    ..This study aimed to perform a prospective evaluation of 18F-NaF and 18F-FDG PET/CT in the detection of occult metastatic disease in men with prostate cancer and biochemical relapse...
  18. doi request reprint Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer
    Eddie Thara
    Division of Cancer Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
    Maturitas 69:296-303. 2011
    ....
  19. ncbi request reprint Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy
    Alexandra M Levine
    Department of Medicine, University of Southern California USC, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 24:1712-9. 2006
    ..This study established the safety, biologic effects, and pharmacokinetics of VEGF-AS in 51 patients with advanced malignancies...
  20. ncbi request reprint Microscopic and gross extravesical extension in pathological staging of bladder cancer
    Marcus L Quek
    Department of Urology, Kenneth Norris, Jr Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, 90089, USA
    J Urol 171:640-5. 2004
    ..We evaluated clinical outcomes in patients with pathological microscopic (pT3a) and gross (pT3b) extravesical tumor extension with transitional cell carcinoma (TCC) of the bladder following radical cystectomy...
  21. ncbi request reprint Natural history of surgically treated bladder carcinoma with extravesical tumor extension
    Marcus L Quek
    Department of Urology, Kenneth Norris Jr Comprehensive Cancer Center, University of Southern California Keck School of Medicine, MS 74, 1441 Eastlake Avenue, Suite 7476, Los Angeles, CA, USA
    Cancer 98:955-61. 2003
    ..The authors evaluated the outcomes of patients with pT3a and pT3b disease after radical cystectomy...
  22. pmc Targeted α-particle therapy of bone metastases in prostate cancer
    Hossein Jadvar
    From the Divisions of Nuclear Medicine, Department of Radiology, and Cancer Medicine, Department of Medicine, Kenneth J Norris Jr Comprehensive CancerCenter, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA
    Clin Nucl Med 38:966-71. 2013
    ..It is anticipated that, with the current emergence of 223Ra as a viable form of therapy, interest in and use of α-particle therapy in the management of cancer will grow...
  23. doi request reprint Factors influencing post-recurrence survival in bladder cancer following radical cystectomy
    Anirban P Mitra
    Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    BJU Int 109:846-54. 2012
    ..To identify prognostic indicators that influence post-recurrence survival following radical cystectomy for bladder cancer...
  24. doi request reprint Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience
    Tanya B Dorff
    USC Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA
    World J Urol 27:39-44. 2009
    ....
  25. ncbi request reprint The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy
    Ana M Aparicio
    Division of Medical Oncology and Kenneth J Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Urol Clin North Am 32:217-30, vii. 2005
    ..The chemotherapy of urological malignancies, including bladder cancer, has recently been reviewed in detail; this article does not contain an extensive review of the drugs used...
  26. ncbi request reprint Molecular prognostic factors in bladder cancer
    Maurizio Buscarini
    Department of Urology, Kenneth Norris Jr Comprehensive Cancer Center, University of Southern Californua Keck School of Medicine, Los Angeles, California 90089, USA
    BJU Int 95:739-42. 2005
  27. ncbi request reprint Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression
    Chia Wei Cheng
    Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, CA 90089, USA
    Cell Stem Cell 14:810-23. 2014
    ..These findings link the reduced levels of IGF-1 caused by fasting to PKA signaling and establish their crucial role in regulating hematopoietic stem cell protection, self-renewal, and regeneration. ..
  28. doi request reprint Novel tyrosine kinase inhibitors for renal cell carcinoma
    Tanya B Dorff
    Department of Medicine, USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave 3440, Los Angeles, CA 90033, USA
    Expert Rev Clin Pharmacol 7:67-73. 2014
    ..New pathways being targeted include FGF, angiopoietin and MET. In this review, we highlight five novel tyrosine kinase inhibitors in development for RCC: tivozanib; dovitinib; regorafenib; cabozantinib; and tivantinib. ..
  29. pmc Tivozanib in the treatment of renal cell carcinoma
    Mehmet Hepgur
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA
    Biologics 7:139-48. 2013
    ..Finally, we discuss the future potential of tivozanib in combination, biomarkers associated with tivozanib response, and acquisition of resistance and nonkidney cancer indications. ..
  30. doi request reprint Small cell bladder cancer: biology and management
    Elie Fahed
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Semin Oncol 39:615-8. 2012
    ..Better understanding of the molecular alterations driving SCBC may facilitate the development of new therapeutic strategies and improved outcomes...
  31. pmc Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study
    Kathleen Ell
    School of Social Work, University of Southern California, Los Angeles, CA 90089 0411, USA
    Gen Hosp Psychiatry 29:223-31. 2007
    ..The primary goal is to test the effectiveness of socioculturally tailored collaborative care intervention in improving depression and quality of life outcomes among low-income ethnic minority patients with major depression and cancer...
  32. pmc Targeted therapy in renal cancer
    Tanya B Dorff
    Assistant Professors of Medicine, Kenneth J Norris Comprehensive Cancer Center, Section of Genitourinary Medical Oncology, Division of Cancer Medicine and Blood Diseases, University of Southern California, Los Angeles CA, USA
    Ther Adv Med Oncol 1:183-205. 2009
    ..This review focuses on the background, clinical development and practical use of these new drugs in RCC...
  33. ncbi request reprint Pain management, supportive and palliative care in patients with renal cell carcinoma
    Jeffrey S Turner
    Kenneth J Norris Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    BJU Int 99:1305-12. 2007
  34. pmc Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum
    John B Welsh
    Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 100:3410-5. 2003
    ....
  35. ncbi request reprint A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer
    Ilias Cagiannos
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 170:1798-803. 2003
    ..We developed a preoperative nomogram for prediction of lymph node metastases in patients with clinically localized prostate cancer...
  36. ncbi request reprint SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4772-81. 2003
    ..Efficacy was correlated with serial plasma VEGF and plasminogen activator inhibitor-1 levels and with positron emission tomography scans...
  37. ncbi request reprint Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy
    Susan M Henshall
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, NSW 2010, Australia
    J Natl Cancer Inst 98:1420-4. 2006
    ....
  38. ncbi request reprint Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion
    David I Quinn
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
    Cancer 97:1884-93. 2003
    ..Predicting outcome for men with clinically localized prostate carcinoma treated with curative intent remains imprecise and further evaluation of accepted and potential predictive factors is needed...
  39. ncbi request reprint A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases
    Primo N Lara
    University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
    Clin Cancer Res 12:1556-63. 2006
    ..Serial serum and urine specimens were collected to assess for markers of bone metabolism...
  40. ncbi request reprint Angiogenesis-targeted therapies in prostate cancer
    Primo N Lara
    University of California Davis Cancer Center, 4501 X St, Suite 3016, Sacramento, CA 95817, USA
    Clin Prostate Cancer 3:165-73. 2004
    ..This review summarizes the molecular mechanisms implicating angiogenesis in the development and progression of advanced-stage prostate cancer, as well as the drug development efforts that are targeting this process...
  41. ncbi request reprint International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy
    Markus Graefen
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3206-12. 2002
    ..We applied this nomogram to patients from seven different institutions spanning three continents...
  42. ncbi request reprint Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse
    Susan M Henshall
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Darlinghurst, Sydney, New South Wales 2010, Australia
    Cancer Res 63:4196-203. 2003
    ....
  43. ncbi request reprint Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer
    Susan M Henshall
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, 384 Victoria Street, Darlinghurst NSW 2010, Australia
    Oncogene 22:6005-12. 2003
    ..These findings are consistent with a role for ZnT4 in vesicular transport of zinc to the cell membrane and potentially in efflux of zinc in the prostate...
  44. ncbi request reprint Is year of radical prostatectomy a predictor of outcome in prostate cancer?
    Ilias Cagiannos
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:692-6. 2004
    ..We examined whether the year in which radical prostatectomy (RP) was performed is a predictor of treatment outcome after controlling for standard prognostic factors...
  45. ncbi request reprint Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients
    Mark E Newell
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Cancer 100:2627-36. 2004
    ....
  46. ncbi request reprint Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer
    Markus Graefen
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:951-6. 2002
    ..We evaluated the predictive accuracy of the nomogram when applied to patients of four international institutions...
  47. ncbi request reprint Postchemotherapy residual masses in advanced seminoma: current management and outcomes
    Marcus L Quek
    Department of Urology, Loyola University Stritch School of Medicine, IL 60153, USA
    Expert Rev Anticancer Ther 5:869-74. 2005
    ..The incorporation of noninvasive imaging modalities, such as positron emission tomography, into the management algorithm may better delineate the presence of viable residual tumor and thus allow better risk stratification...
  48. ncbi request reprint Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Charles A Sammons Cancer Center, Dallas, TX 75254, USA
    Clin Genitourin Cancer 4:181-6. 2005
    ..Until results from ongoing trials clearly demonstrate superiority of newer agents over IFN-alpha or IL-2, these agents should remain a standard of care for the treatment of RCC...
  49. doi request reprint The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial
    Karen G Chee
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Genitourin Cancer 5:433-7. 2007
    ..Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer...
  50. ncbi request reprint A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
    Walter M Stadler
    Department of Medicine, Section of Hematology Oncology and Urology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 61:689-94. 2008
    ..GTI-2040 is a 20-mer phosphorothioate oligonucleotide complimentary to the R2 component of ribonucleotide reductase that has activity in renal cancer models...
  51. ncbi request reprint Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 1:126-34. 2006
    ..This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors...
  52. ncbi request reprint Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer 106:2624-9. 2006
    ..To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed...